Helicobacter Pylori Infections Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Phathom Pharma, HK inno.N Corp, Elpen Pharma, Deva Holding, Lallemand Health, Takeda, Meridian Bioscience, Janssen Cila

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Helicobacter Pylori Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Helicobacter Pylori Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Helicobacter Pylori Infections Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Helicobacter Pylori Infections Market.

The Helicobacter Pylori Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Helicobacter Pylori Infections Pipeline Report: https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Helicobacter Pylori Infections treatment therapies with a considerable amount of success over the years.
• Helicobacter Pylori Infections companies working in the treatment market are Servatus Biopharmaceuticals, TenNor Therapeutics (Suzhou) Limited, Phathom Pharmaceuticals, Inc., HK inno.N Corporation, Elpen Pharmaceutical Co. Inc., Deva Holding A.S., Lallemand Health Solutions, Takeda, Meridian Bioscience, Inc., Janssen Cilag Pharmaceutica S.A.C.I., Greece, RedHill Biopharma Limited, Il-Yang Pharm. Co., Ltd., Asan Medical Center, MerLion Pharmaceuticals GmbH, TenNor Therapeutics (Suzhou) Limited, and others, are developing therapies for the Helicobacter Pylori Infections treatment
• Emerging Helicobacter Pylori Infections therapies in the different phases of clinical trials are- SVT1C4610, TNP-2198, Vonoprazan, Tegoprazan, Esomeprazole, Levofloxacin, Lacidofil, CJ-12420/Clarithromycin/AmoxicillinVonoprazan, Vonoprazan, Lansoprazole (Lanton), rabeprazole sodium, RHB-105, Ilaprazole + Amoxicillin, pantoprazole, Finafloxacin + Amoxicillin, Rifasutenizol capsules, and others are expected to have a significant impact on the Helicobacter Pylori Infections market in the coming years.
• In November 2024, TenNor Therapeutics has revealed that its antibiotic candidate, rifasutenizol, has successfully met all primary endpoints in a Phase III trial, outperforming the current standard of care (SoC). The multicenter, randomized, double-blind, controlled trial (NCT05857163) demonstrated that rifasutenizol triple therapy achieved an eradication rate of over 90%, surpassing the effectiveness of bismuth-containing quadruple therapy (BQT) in treating Helicobacter pylori (H. pylori) infection, a prevalent bacterial infection of the stomach often responsible for stomach ulcers.
• In March 2024, The stool antigen test (SAT) and serum Helicobacter pylori (H. pylori) IgG antibody assays are highly effective in diagnosing H. pylori infections and differentiating between acute and chronic cases. This study aimed to assess the diagnostic value of serum H. pylori IgG antibodies and SAT in detecting H. pylori infections among patients with chronic H. pylori infection in Ibb Governorate, Yemen. A total of 200 patients, confirmed to have H. pylori infection through positive results from the serum immunochromatographic antibody test, were selected for further confirmation using serum H. pylori IgG antibodies and SAT at various hospitals and gastroenterology and hepatology clinics in Ibb Governorate.

Helicobacter Pylori Infections Overview
Helicobacter pylori (H. pylori) infection is a bacterial infection that affects the stomach lining. It is one of the most common infections worldwide and is often acquired in childhood. H. pylori can cause chronic inflammation of the stomach, leading to conditions such as gastritis, peptic ulcers, and an increased risk of stomach cancer. The infection is usually asymptomatic, but when symptoms occur, they may include stomach pain, bloating, nausea, and indigestion. H. pylori infections are typically treated with a combination of antibiotics and acid-suppressing medications to eradicate the bacteria and promote healing.

Get a Free Sample PDF Report to know more about Helicobacter Pylori Infections Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Helicobacter Pylori Infections Drugs Under Different Phases of Clinical Development Include:
• SVT1C4610: Servatus Biopharmaceuticals
• TNP-2198: TenNor Therapeutics (Suzhou) Limited
• Vonoprazan: Phathom Pharmaceuticals, Inc.
• Tegoprazan: HK inno.N Corporation
• Esomeprazole: Elpen Pharmaceutical Co. Inc.
• Levofloxacin: Deva Holding A.S.
• Lacidofil: Lallemand Health Solutions
• CJ-12420/Clarithromycin/AmoxicillinVonoprazan: HK inno.N Corporation
• Vonoprazan: Takeda
• Lansoprazole (Lanton): Meridian Bioscience, Inc.
• rabeprazole sodium: Janssen Cilag Pharmaceutica S.A.C.I., Greece
• RHB-105: RedHill Biopharma Limited
• Ilaprazole + Amoxicillin: Il-Yang Pharm. Co., Ltd.
• pantoprazole: Asan Medical Center
• Finafloxacin + Amoxicillin: MerLion Pharmaceuticals GmbH
• Rifasutenizol capsules: TenNor Therapeutics (Suzhou) Limited

Helicobacter Pylori Infections Route of Administration
Helicobacter Pylori Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Helicobacter Pylori Infections Molecule Type
Helicobacter Pylori Infections Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Helicobacter Pylori Infections Pipeline Therapeutics Assessment
• Helicobacter Pylori Infections Assessment by Product Type
• Helicobacter Pylori Infections By Stage and Product Type
• Helicobacter Pylori Infections Assessment by Route of Administration
• Helicobacter Pylori Infections By Stage and Route of Administration
• Helicobacter Pylori Infections Assessment by Molecule Type
• Helicobacter Pylori Infections by Stage and Molecule Type

DelveInsight's Helicobacter Pylori Infections Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Helicobacter Pylori Infections product details are provided in the report. Download the Helicobacter Pylori Infections pipeline report to learn more about the emerging Helicobacter Pylori Infections therapies
https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr


Some of the key companies in the Helicobacter Pylori Infections Therapeutics Market include:
Key companies developing therapies for Helicobacter Pylori Infections are - Takeda Pharmaceutical, AbbVie, Cumberland Pharmaceuticals, Eisai Co, Bio-Rad Laboratories, F. Hoffmann-La, Roche, Alpha Laboratories, Biohit, Biomerica, Inc., QuickNaviTM, and others.

Helicobacter Pylori Infections Pipeline Analysis:
The Helicobacter Pylori Infections pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Helicobacter Pylori Infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Helicobacter Pylori Infections Treatment.
• Helicobacter Pylori Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Helicobacter Pylori Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Helicobacter Pylori Infections market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Helicobacter Pylori Infections drugs and therapies
https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Helicobacter Pylori Infections Pipeline Drug Insight
• Coverage: Global
• Key Helicobacter Pylori Infections Companies: Servatus Biopharmaceuticals, TenNor Therapeutics (Suzhou) Limited, Phathom Pharmaceuticals, Inc., HK inno.N Corporation, Elpen Pharmaceutical Co. Inc., Deva Holding A.S., Lallemand Health Solutions, Takeda, Meridian Bioscience, Inc., Janssen Cilag Pharmaceutica S.A.C.I., Greece, RedHill Biopharma Limited, Il-Yang Pharm. Co., Ltd., Asan Medical Center, MerLion Pharmaceuticals GmbH, TenNor Therapeutics (Suzhou) Limited, and others
• Key Helicobacter Pylori Infections Therapies: SVT1C4610, TNP-2198, Vonoprazan, Tegoprazan, Esomeprazole, Levofloxacin, Lacidofil, CJ-12420/Clarithromycin/AmoxicillinVonoprazan, Vonoprazan, Lansoprazole (Lanton), rabeprazole sodium, RHB-105, Ilaprazole + Amoxicillin, pantoprazole, Finafloxacin + Amoxicillin, Rifasutenizol capsules, and others
• Helicobacter Pylori Infections Therapeutic Assessment: Helicobacter Pylori Infections current marketed and Helicobacter Pylori Infections emerging therapies
• Helicobacter Pylori Infections Market Dynamics: Helicobacter Pylori Infections market drivers and Helicobacter Pylori Infections market barriers

Request for Sample PDF Report for Helicobacter Pylori Infections Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Helicobacter Pylori Infections Report Introduction
2. Helicobacter Pylori Infections Executive Summary
3. Helicobacter Pylori Infections Overview
4. Helicobacter Pylori Infections- Analytical Perspective In-depth Commercial Assessment
5. Helicobacter Pylori Infections Pipeline Therapeutics
6. Helicobacter Pylori Infections Late Stage Products (Phase II/III)
7. Helicobacter Pylori Infections Mid Stage Products (Phase II)
8. Helicobacter Pylori Infections Early Stage Products (Phase I)
9. Helicobacter Pylori Infections Preclinical Stage Products
10. Helicobacter Pylori Infections Therapeutics Assessment
11. Helicobacter Pylori Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Helicobacter Pylori Infections Key Companies
14. Helicobacter Pylori Infections Key Products
15. Helicobacter Pylori Infections Unmet Needs
16 . Helicobacter Pylori Infections Market Drivers and Barriers
17. Helicobacter Pylori Infections Future Perspectives and Conclusion
18. Helicobacter Pylori Infections Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Helicobacter Pylori Infections Market https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Helicobacter Pylori Infections-Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Helicobacter Pylori Infections Epidemiology https://www.delveinsight.com/report-store/helicobacter-pylori-infections-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Helicobacter Pylori Infections Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market
• Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market
• Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.